Clinical Trials Logo

Clinical Trial Summary

In this Phase 1/2 study, the investigators will conduct a safety and efficacy study of the combination of BMX-001 with standard radiation therapy (RT) and concurrent 5-fluorouracil (5FU)/mitomycin in newly diagnosed Anal Squamous Cell Carcinoma (ASCC) patients. The primary objectives are: Phase 1 - is to determine the maximum tolerated dose (MTD) of BMX-001 in ASCC patients receiving RT and concurrent 5FU/mitomycin chemotherapy.2. For phase II part: To examine the impact of BMX-001 on the overall acute ≥ grade 3 toxicity rate of the normal tissue including rectum, bladder, and skin in combination with RT and concurrent 5FU/mitomycin in treatment of newly diagnosed ASCC patients


Clinical Trial Description

In this Phase 1/2 study, the investigators will conduct a safety and efficacy study of the combination of BMX-001 with standard radiation therapy (RT) and concurrent 5-fluorouracil (5FU)/mitomycin in newly diagnosed Anal Squamous Cell Carcinoma (ASCC) patients. At the time of writing of this protocol amendment, another Phase 1 study using BMX-001 with concurrent chemotherapy and radiation therapy in patient with newly diagnosed high-grade gliomas (BMX-HGG-001) has completed. This clinical trial has demonstrated no adverse effects in subcutaneous dosing up to 28 mg/subject load with half the loading dose (14 mg/subject) given biweekly for 8 weeks in 12 subjects. Three subjects were enrolled and dosed with 42 mg/subject load with half the loading dose given biweekly for 8 weeks. Of these three subjects, there was one dose-limiting toxicity of grade 3 tachycardia and grade 3 hypotension. The DLT in this subject occurred with the loading dose (42 mg sc). The patient was treated with fluids and hospital admitted for observation for 24 hours during which time the hypotension and tachycardia resolved. The cardiac rhythm was a sinus tachycardia and no other cardiac toxicity was observed. The tachycardia was assumed to have resulted from hypotension occurring following the sub-cutaneous injection of BMX-001 (42 mg). After the loading dose of BMX-001 and the described DLT, the subject continued on study and experienced no tachycardia or hypotension following administration of the subsequent 16 maintenance doses (20 mg sc). The sponsor determined that the Recommended Phase 2 Dose (RP2D) of BMX-001 is 28 mg/subject load followed by 14 mg/subject twice a week for up to eight weeks. This is the maximum dose that was tolerated with no adverse effects. The most common related toxicity seen in the Phase 1 BMX-HGG-001 trial was grade 1 injection site reaction. There is no apparent toxicity to end organ tissues or bone marrow. The completion of a Phase 1 clinical trial in patients with high-grade glioma undergoing brain radiation therapy plus chemotherapy with temozolomide has established the RP2D for BMX-001. The RP2D by sub-cutaneous injection is 28 mg/subject load followed by a maintenance dose of 14 mg/subject b.i.w. At the RP2D, there have been no BMX-001 dose limiting toxicities observed. Based on the completion of Phase 1 and establishment of a RP2D for this treatment regimen in patients undergoing radiation therapy and chemotherapy, the clinical trial described in this protocol of patients with newly diagnosed ASCC will proceed to Dose Level 3, after completion of Dose Level 1 and Dose Level 2, enrolling up to 20 subjects with a safety lead-in of 6 subjects. The reason for the safety lead-in is to confirm safety in subjects in this cohort receiving radiation therapy and 5FU/mitomycin. In order to evaluate the pharmacokinetics (PK) of BMX-001 in combination with current chemoradiation, blood samples will be drawn for analysis in the a minimum of three and up to 6 patients in enrolled in the safety lead-in. In this trial, the first dose of BMX-001 will be administered subcutaneously from 4 days up to 1 hour prior to the start of radiation treatment. Blood will be drawn for PK on the following days: Day 1 (before and after loading dose), Day 8, Day 22 and Day 36. Measures will be obtained at approximately the following times: -1 to 0 hour (before loading dose), 30 minutes after the drug is given, 4 hours post-dose, and 24 hours post-dose. This is described in Appendix A. Samples will be analyzed for BMX-001 using validated analytical methods at Dr. Ivan Spasojevic's laboratory at Duke University. Skin, GI, and GU symptoms will be measured on the day of screening, weekly during RT, 1 months, 4 months and 10 months after the completion of RT. Perianal skin will be assessed weekly during RT, 1 month, 4 months, and 10 months after completion of RT. Further follow up will be per standard of care. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03386500
Study type Interventional
Source University of Nebraska
Contact Jessi E Delaney, RN, BSN
Phone 402-559-8711
Email jessdelaney@unmc.edu
Status Recruiting
Phase Phase 1/Phase 2
Start date November 28, 2017
Completion date December 2029

See also
  Status Clinical Trial Phase
Completed NCT03649451 - Reference Dose Levels During Fluoroscopically Guided Procedures in Operating Rooms
Completed NCT03305978 - Pulmonary Nodule Detection: Comparison of an Ultra Low Dose vs Standard Scan. N/A
Recruiting NCT04139096 - Genetic Susceptibility to Radiation Induced Thyroid Cancer
Completed NCT01430975 - Prospective Evaluation of Strontium in Patients After CardioGen-82 PET MPI Scanning at Two Clinical Sites N/A
Completed NCT01424774 - Prospective Evaluation of Strontium in Patients After CardioGen-82 PET MPI Scanning N/A
Completed NCT00378053 - A Prospective Study of Radiation Exposure to Surgeons N/A
Recruiting NCT05561439 - Individual Dosimetric Monitoring of Workers During Interventional Radiology and Cardiology Procedures for Cardiologists and Radiologists in France
Completed NCT04078165 - Suspended Personal Protection System Versus Conventional Protection (Aka Zero-Gravity vs Shield and Apron) N/A
Recruiting NCT04694391 - Genomic Study of Relapse Esophageal Cancer After Radiotherapy
Not yet recruiting NCT04403815 - Radiation Exposure During Coronary Procedures According to Vascular Access
Recruiting NCT04285944 - Operator Radiation Protection During Cardiac Catheterization Using Mavig X-ray Protective Drapes®. N/A
Completed NCT04363190 - Genomic Instability in Vascular Surgeons
Completed NCT04404257 - Reduce Radiation Exposure in Fluoroscopic Interventions Evaluation N/A
Recruiting NCT04678258 - Zero Fluoroscopy Voltage Guided vs. Linear CTI Ablation N/A
Recruiting NCT05833516 - Hyper Adduction of Right Radial Artery/Arm vs Left Drag Over Technique
Recruiting NCT03946280 - Utility of 3D Navigation to Reduce Ionizing Radiation in Common Flutter Ablation. Study of Personnel and Patient Dosimetry N/A
Completed NCT03985488 - Radiation Exposure Assessment in Fluoroscopy
Completed NCT03605030 - Reducing Radiation Exposure to Operators During Invasive Cardiac Procedures N/A
Recruiting NCT02689908 - Individualized Radiation Dose Control N/A
Completed NCT05347290 - Comparison Of Effective Radiation Shielding Between Rampart IC, M1128 Shield vs Conventional Apron And Shields In Clinical Interventional Procedures N/A